Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration

Michael Thomas,1 Shaymaa S Mousa,2 Shaker A Mousa1 1Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USA; 2The Johns Hopkins University, Baltimore, MD, USA Abstract: Wet age-related macular degeneration (AMD) is the most common reason for vision loss in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Thomas M, Mousa SS, Mousa SA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/5781b0b02da84d49bbdfda4c510ada63
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5781b0b02da84d49bbdfda4c510ada63
record_format	dspace
spelling	oai:doaj.org-article:5781b0b02da84d49bbdfda4c510ada632021-12-02T01:46:56ZComparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration1177-54671177-5483https://doaj.org/article/5781b0b02da84d49bbdfda4c510ada632013-03-01T00:00:00Zhttp://www.dovepress.com/comparative-effectiveness-of-aflibercept-for-the-treatment-of-patients-a12414https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Michael Thomas,1 Shaymaa S Mousa,2 Shaker A Mousa1 1Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USA; 2The Johns Hopkins University, Baltimore, MD, USA Abstract: Wet age-related macular degeneration (AMD) is the most common reason for vision loss in the United States. Many treatments, such as laser therapy and photodynamic therapies, have been used but their efficacy is limited. Emerging anti-vascular endothelial growth factor (VEGF) therapies are now considered the standard of care. Anti-VEGF agents inhibit angiogenesis in the eye by suppressing abnormal blood vessel growth, leading to vision improvement. Ranibizumab and bevacizumab are two examples of anti-VEGF drugs that have been approved; both showed promise based on the visual acuity scale. Aflibercept, another new therapy known to trap VEGF and inhibit multiple growth factors, is promising not only because it can be taken bimonthly based on year 1 of the VIEW trials, but it can also be extended, as demonstrated in year 2 of the VIEW trials. Based on a cost&ndash;effect analysis, aflibercept is comparable to other leading therapies. This is a review of relevant clinical trials that have proven the non-inferiority and safety of aflibercept compared to the standard of care and its unique role in the current management of wet AMD. Keywords: aflibercept, VEGF, anti-VEGF, pegatanib, bevacizumab, ranibizumab, VIEW trialsThomas MMousa SSMousa SADove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2013, Iss default, Pp 495-501 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Thomas M Mousa SS Mousa SA Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
description	Michael Thomas,1 Shaymaa S Mousa,2 Shaker A Mousa1 1Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USA; 2The Johns Hopkins University, Baltimore, MD, USA Abstract: Wet age-related macular degeneration (AMD) is the most common reason for vision loss in the United States. Many treatments, such as laser therapy and photodynamic therapies, have been used but their efficacy is limited. Emerging anti-vascular endothelial growth factor (VEGF) therapies are now considered the standard of care. Anti-VEGF agents inhibit angiogenesis in the eye by suppressing abnormal blood vessel growth, leading to vision improvement. Ranibizumab and bevacizumab are two examples of anti-VEGF drugs that have been approved; both showed promise based on the visual acuity scale. Aflibercept, another new therapy known to trap VEGF and inhibit multiple growth factors, is promising not only because it can be taken bimonthly based on year 1 of the VIEW trials, but it can also be extended, as demonstrated in year 2 of the VIEW trials. Based on a cost&ndash;effect analysis, aflibercept is comparable to other leading therapies. This is a review of relevant clinical trials that have proven the non-inferiority and safety of aflibercept compared to the standard of care and its unique role in the current management of wet AMD. Keywords: aflibercept, VEGF, anti-VEGF, pegatanib, bevacizumab, ranibizumab, VIEW trials
format	article
author	Thomas M Mousa SS Mousa SA
author_facet	Thomas M Mousa SS Mousa SA
author_sort	Thomas M
title	Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
title_short	Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
title_full	Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
title_fullStr	Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
title_full_unstemmed	Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
title_sort	comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/5781b0b02da84d49bbdfda4c510ada63
work_keys_str_mv	AT thomasm comparativeeffectivenessofafliberceptforthetreatmentofpatientswithneovascularagerelatedmaculardegeneration AT mousass comparativeeffectivenessofafliberceptforthetreatmentofpatientswithneovascularagerelatedmaculardegeneration AT mousasa comparativeeffectivenessofafliberceptforthetreatmentofpatientswithneovascularagerelatedmaculardegeneration
_version_	1718402896491446272

Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration

Ejemplares similares